SEARCH:   Advanced

Blood, 15 December 2008, Vol. 112, No. 13, pp. 4824-4831. Prepublished online as a Blood First Edition Paper on September 17, 2008; DOI 10.1182/blood-2008-04-153189. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-04-153189v1 112/13/4824    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Salles, G. Articles by Foussard, C. Search for Related Content PubMed PubMed Citation Articles by Salles, G. Articles by Foussard, C. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 21, 2008 Accepted August 16, 2008 Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study Gilles Salles*, Nicolas Mounier, Sophie de Guibert, Franck Morschhauser, Chantal Doyen, Jean-Francois Rossi, Corinne Haioun, Pauline Brice, Beatrice Mahe, Reda Bouabdallah, Bruno Audhuy, Christophe Ferme, Caroline Dartigeas, Pierre Feugier, Catherine Sebban, Luc Xerri, and Charles Foussard Hospices Civils de Lyon, UMR CNRS 5239, Pierre-Bénite, France CHU de Nice, Nice, France CHU de Rennes, Rennes, France CHU de Lille, Lille, France UCL- Mont-Godinne, Mont-Godinne, Belgium CHU de Montpellier, Montpelllier, France Hopital Henri-Mondor - AP-HP, Universite Paris XII, Creteil, France Hopital Saint Louis - AP-HP, Paris, France CHU de Nantes, Nantes, France Institut Paoli-Calmettes, Marseille, France CH de Colmar, Colmar, France Institut Gustave Roussy, Villejuif, France CHU de Tours, Tours, France CHU de Nancy, Nancy, France Centre Leon Berard, Lyon, France CHU d'Angers, Angers, France * Corresponding author; email: gilles.salles{at}chu-lyon.fr. The FL2000 study was undertaken to evaluate the combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy plus interferon in the first line treatment of follicular lymphoma patients with a high tumor burden. Patients were randomly assigned to receive either 12 courses of the chemotherapy regimen CHVP (cyclophosphamide, adriamycin, etoposide and prednisolone) plus interferon-2a (CHVP+I arm) over 18 months or 6 courses of the same chemotherapy regimen combined with 6 infusions of 375 mg/m2 of rituximab and interferon for the same time period (R-CHVP+I arm). After a median follow-up of five years, event-free survival estimates were respectively 37% [95% C.I. 29 - 44] and 53% [95% C.I. 45 - 60] in the CHVP+I and R-CHVP+I arm (P=.0004). Five years overall survival estimates were not statistically different in the CHVP+I (79%) [95% C.I. 72 - 84]) and R-CHVP+I (84% [95% C.I. 78 - 84]) arms. In a multivariate regression analysis, event free survival was significantly influenced by both the Follicular Lymphoma International Prognostic Index (FLIPI) score (HR=2.08; 95% C.I. [1.6 - 2.8]) and the treatment arm (HR=0.59; 95% C.I. [0.44 - 0.78]). With a five year follow-up, the combination of rituximab with CHVP+I provides superior disease control in follicular lymphoma patients despite a shorter duration of chemotherapy. This study's clinical trial was deposited on the National Institute of Health website (NCT00136552) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. B. Delaloye, C. Antonescu, T. Louton, J. Kuhlmann, and A. Hagenbeek Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial J. Nucl. Med., November 1, 2009; 50(11): 1837 - 1843. [Abstract] [Full Text] [PDF] E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C.-H. Chang CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood, October 29, 2009; 114(18): 3864 - 3871. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF] H. Hochster, E. Weller, R. D. Gascoyne, T. M. Habermann, L. I. Gordon, T. Ryan, L. Zhang, N. Colocci, S. Frankel, and S. J. Horning Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study J. Clin. Oncol., April 1, 2009; 27(10): 1607 - 1614. [Abstract] [Full Text] [PDF] A. Hagenbeek Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand? J. Clin. Oncol., April 1, 2009; 27(10): 1540 - 1542. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020